🇺🇸 FDA
Pipeline program

-, IPTACOPAN, -, -, -

CLNP023A2002B

Approved small_molecule active

Quick answer

-, IPTACOPAN, -, -, - for IgA Nephropathy is a Approved program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).

Program details

Company
Novartis Ophthalmics Europe
Indication
IgA Nephropathy
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials